Furthermore, combination therapy showed enhanced antitumor activity in preclinical studies of a HER2-positive human gastric cancer xenograft model [37] and is being tested for patients with HER2-positive gastric cancer as part of an international phase III trial [38]. Here, ERBB2 is linked to gastric cancer.